Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens

Conclusions: PD-1/PD-L1 inhibitors have a lower risk of developing diarrhea than chemotherapy and CTLA-4 inhibitor. There is no direct relationship between the dose of PD-1/PD-L1 inhibitors and the risk of developing diarrhea.

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Lei Zhao, Jing Yu, Jing Wang, Huihui Li, Juanjuan Che, Bangwei Cao Tags: Research Paper Source Type: research